COL11A2

Summary

COL11A2 (collagen type XI alpha 2 chain, HGNC:2187) is a protein-coding gene on chromosome 6p21.32, encoding Collagen alpha-2(XI) chain (P13942). May play an important role in fibrillogenesis by controlling lateral growth of collagen II fibrils.

This gene encodes one of the two alpha chains of type XI collagen, a minor fibrillar collagen. It is located on chromosome 6 very close to but separate from the gene for retinoid X receptor beta. Type XI collagen is a heterotrimer but the third alpha chain is a post-translationally modified alpha 1 type II chain. Proteolytic processing of this type XI chain produces PARP, a proline/arginine-rich protein that is an amino terminal domain. Mutations in this gene are associated with type III Stickler syndrome, otospondylomegaepiphyseal dysplasia (OSMED syndrome), Weissenbacher-Zweymuller syndrome, autosomal dominant non-syndromic sensorineural type 13 deafness (DFNA13), and autosomal recessive non-syndromic sensorineural type 53 deafness (DFNB53). Alternative splicing results in multiple transcript variants. A related pseudogene is located nearby on chromosome 6.

Source: NCBI Gene 1302 — RefSeq curated summary.

At a glance

• Gene–disease (curated): nonsyndromic genetic hearing loss (Definitive, ClinGen) — +8 more curated relationships
• GWAS associations: 13
• Clinical variants (ClinVar): 3,179 total — 109 pathogenic, 70 likely-pathogenic
• Phenotypes (HPO): 103
• Druggable target: yes
• MANE Select transcript: NM_080680

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:2187
Approved symbol	COL11A2
Name	collagen type XI alpha 2 chain
Location	6p21.32
Locus type	gene with protein product
Status	Approved
Aliases	HKE5
Ensembl gene	ENSG00000204248
Ensembl biotype	protein_coding
OMIM	120290
Entrez	1302

Gene structure

Transcript identifiers

Ensembl transcripts: 9 — 6 protein_coding, 2 protein_coding_CDS_not_defined, 1 retained_intron

ENST00000341947, ENST00000361917, ENST00000374708, ENST00000395194, ENST00000477772, ENST00000682718, ENST00000683572, ENST00000930121, ENST00000930122

RefSeq mRNA: 9 — MANE Select: NM_080680 NM_001163771, NM_001424108, NM_001424109, NM_001424110, NM_001424111, NM_001424112, NM_080679, NM_080680, NM_080681

CCDS: CCDS43452, CCDS54992

Canonical transcript exons

ENST00000341947 — 66 exons

Exon	Start	End
ENSE00001591917	33180258	33180332
ENSE00001593142	33167426	33167533
ENSE00001593801	33168519	33168572
ENSE00001597212	33174011	33174055
ENSE00001609033	33176433	33176486
ENSE00001611495	33186627	33186818
ENSE00001614950	33173502	33173555
ENSE00001619060	33178435	33178488
ENSE00001619517	33179719	33179805
ENSE00001626108	33166720	33166827
ENSE00001628318	33185701	33185778
ENSE00001628677	33169831	33169884
ENSE00001637522	33176259	33176303
ENSE00001638395	33170047	33170100
ENSE00001639420	33179073	33179126
ENSE00001644841	33165931	33165984
ENSE00001649396	33180964	33181005
ENSE00001651242	33175574	33175681
ENSE00001654686	33171713	33171820
ENSE00001656329	33167264	33167317
ENSE00001657383	33173348	33173401
ENSE00001657965	33178308	33178352
ENSE00001661993	33178920	33178973
ENSE00001662669	33169383	33169490
ENSE00001662847	33189320	33189469
ENSE00001669897	33176992	33177045
ENSE00001675003	33170557	33170610
ENSE00001683081	33173701	33173745
ENSE00001686146	33180668	33180730
ENSE00001694501	33170810	33170917
ENSE00001695581	33168955	33169008
ENSE00001697052	33178679	33178732
ENSE00001700159	33168706	33168759
ENSE00001700512	33171114	33171167
ENSE00001700606	33179231	33179284
ENSE00001703905	33172289	33172378
ENSE00001711154	33188978	33189188
ENSE00001715928	33173060	33173113
ENSE00001716900	33171271	33171324
ENSE00001720958	33192159	33192467
ENSE00001722047	33170326	33170379
ENSE00001727720	33174527	33174580
ENSE00001734399	33172050	33172103
ENSE00001743451	33184145	33184324
ENSE00001748428	33188362	33188524
ENSE00001750553	33167070	33167123
ENSE00001751603	33176016	33176069
ENSE00001755693	33179431	33179487
ENSE00001760832	33174165	33174218
ENSE00001762215	33184992	33185054
ENSE00001768778	33166171	33166206
ENSE00001769361	33167799	33167852
ENSE00001778927	33166513	33166566
ENSE00001779499	33171467	33171574
ENSE00001784208	33173873	33173926
ENSE00001786461	33181111	33181170
ENSE00001788381	33176721	33176765
ENSE00001788499	33172530	33172637
ENSE00003544722	33177181	33177225
ENSE00003547073	33177662	33177706
ENSE00003551264	33177412	33177465
ENSE00003556456	33164267	33164473
ENSE00003574544	33165549	33165816
ENSE00003634445	33164852	33164964
ENSE00003784884	33178132	33178185
ENSE00003897062	33162694	33163818

Expression profiles

Bgee: expression breadth ubiquitous, 134 present calls, max score 88.77.

FANTOM5 (CAGE): breadth broad, TPM avg 4.4334 / max 632.0300, expressed in 318 samples.

FANTOM5 promoters (7 alternative TSS)

Promoter ID	TPM avg	Samples expressed
73100	4.1706	258
73090	0.1013	66
73097	0.0489	16
73099	0.0437	14
73098	0.0385	11
73091	0.0192	4
73096	0.0112	6

Top tissues by expression

148 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
pituitary gland	UBERON:0000007	88.77	gold quality
male germ line stem cell (sensu Vertebrata) in testis	CL:0000089 ∩ UBERON:0000473	88.70	gold quality
adenohypophysis	UBERON:0002196	87.53	gold quality
right hemisphere of cerebellum	UBERON:0014890	86.95	gold quality
cerebellar hemisphere	UBERON:0002245	86.55	gold quality
cerebellar cortex	UBERON:0002129	86.46	gold quality
cerebellum	UBERON:0002037	85.82	gold quality
C1 segment of cervical spinal cord	UBERON:0006469	81.96	gold quality
spinal cord	UBERON:0002240	81.93	gold quality
putamen	UBERON:0001874	78.85	gold quality
right frontal lobe	UBERON:0002810	78.72	gold quality
substantia nigra	UBERON:0002038	77.71	gold quality
Ammon’s horn	UBERON:0001954	77.25	gold quality
central nervous system	UBERON:0001017	76.73	gold quality
brain	UBERON:0000955	76.55	gold quality
Brodmann (1909) area 9	UBERON:0013540	76.32	gold quality
caudate nucleus	UBERON:0001873	76.30	gold quality
nucleus accumbens	UBERON:0001882	75.89	gold quality
left testis	UBERON:0004533	75.80	gold quality
right testis	UBERON:0004534	75.48	gold quality
primary visual cortex	UBERON:0002436	75.44	gold quality
hypothalamus	UBERON:0001898	75.31	gold quality
amygdala	UBERON:0001876	74.89	gold quality
testis	UBERON:0000473	74.74	gold quality
temporal lobe	UBERON:0001871	74.55	gold quality
dorsolateral prefrontal cortex	UBERON:0009834	74.34	gold quality
ventricular zone	UBERON:0003053	74.11	gold quality
superior frontal gyrus	UBERON:0002661	73.16	gold quality
cortical plate	UBERON:0005343	73.08	gold quality
anterior cingulate cortex	UBERON:0009835	72.60	gold quality

Single-cell (SCXA)

Detected in 2 experiment(s), a significant marker in 0.

Experiment	Marker?	Max mean expression
E-GEOD-75367	no	49.88
E-ANND-3	no	0.91

Regulation

Is transcription factor: no

Upstream regulators (CollecTRI, top): CTCF, ERG, EWSR1, HMGA2, MAF, SOX10, SOX9, SP1, SP3, SP7, ZNF219, ZNF250, ZNF263

miRNA regulators (miRDB)

12 targeting COL11A2, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-8075	99.97	67.20	962
HSA-MIR-6842-5P	99.80	67.54	1587
HSA-MIR-7110-5P	99.80	67.84	1712
HSA-MIR-8061	99.63	69.44	1411
HSA-MIR-6752-5P	99.59	67.32	1243
HSA-MIR-1224-5P	99.48	65.59	803
HSA-MIR-130A-5P	99.33	70.26	2623
HSA-MIR-4478	99.07	65.16	2320
HSA-MIR-6760-5P	98.87	66.73	1515
HSA-MIR-6804-5P	98.39	65.77	1084
HSA-MIR-3929	98.32	65.58	1026
HSA-MIR-3162-5P	95.67	67.53	794

Literature-anchored findings (GeneRIF, showing 29)

• differential regulation by EWS/ERG sarcoma fusion protein and wild-type ERG (PMID:12554743)
• sequence variations in these genes can play a role in the etiology of Robin sequence, cleft palate and micrognathia but are not common causes of these phenotypes. (PMID:12673280)
• Mutation in the COL11A2 gene was found in all affected individuals, which lends molecular support to the clinical notion that autosomal recessive Weissenbacher-Zweymuller syndrome (WZS) and otospondylomegaepiphyseal dysplasia (OSMED)are a single entity. (PMID:15558753)
• mutation type and location are critical determinants in defining the phenotype of COL11A2 associated diseases (PMID:16033917)
• COL11A2 transcription is regulated by Sp1 proteins and by binding to its proximal promoter (PMID:16734381)
• This study is the first to show that collagen XI is present in the Golgi apparatus of normal human colon goblet cells and localizes collagen XI in both normal and malignant tissue. (PMID:18040076)
• diagnosis ofOtospondylomegaepiphyseal dysplasia was diagnosed by identifying a mutation in the COL11A2 gene that encodes the pre-pro-alpha2(XI) chain of type XI collagen that is involved in type II collagen fibrillogenesis. (PMID:18381781)
• individuals carrying the C allele at the COL11A2 SNP site, rs2076311, had a lower risk of Kawasaki disease and had a lower probability of developing coronary artery lesions (PMID:20618517)
• implication of IRF6, COL2A1, and WNT3 in occurrence of nonsyndromic cleft palate (NSCP); likely variation in cartilage collagen II and XI genes, IRF6, and Wnt and FGF signal pathway genes contributes susceptibility to NSCP in Northeast Europe populations (PMID:20672350)
• A novel homozygous COL11A2 deletion causes a C-terminal protein truncation with incomplete mRNA decay in a Turkish patient. (PMID:21204229)
• four loci showed the strongest associations with RA (P<0.005): ZNF391, OR2H1, C6orf26-RDBP and HLA-DPB1-COL11A2. (PMID:21293383)
• The findings of a significant association between lip and/or palate clefts and two markers in the WNT3 and COL11A2 genes were the most consistent and were observed in all groups analysed and stratified. (PMID:22112025)
• These findings thus demonstrate that fibrochondrogenesis can result from either recessively or dominantly inherited mutations in COL11A2 (PMID:22246659)
• Hearing impairment in non-ocular Stickler syndrome is characterized by non-progressive hearing loss, present since childhood, and mostly mild to moderate in severity. Heterozygote mutations in COL11A2 were present in two pedigrees. (PMID:22796475)
• results show that this gene interacts collagen x1 encoded genes to modulate the risk for AT (PMID:23624467)
• Expanded spectrum of mutations in the COL11A1 and COL11A2 genes in Stickler syndrome. (PMID:25240749)
• Data indicate that Ala37Ser is the missense mutation located in the NC4 domain of the collagen type XI COL11A2 protein. (PMID:25633957)
• A novel mutation in COL11A2 was found in a Japanese family with non-ocular Stickler syndrome. (PMID:25780254)
• Up to now, merely 7 loci have been linked to mid-frequency hearing loss. Only four genetic mid-frequency deafness genes, namely, DFNA10 (EYA4), DFNA8/12 (TECTA), DFNA13 (COL11A2), DFNA44 (CCDC50), have been reported to date. [review] (PMID:27142990)
• Missense mutations in COL6A1, COL11A2, FGFR1, and BMP2 genetically predispose patients to ossification of posterior longitudinal ligaments. (PMID:27246988)
• that the COL11A2 gene, which has previously been associated with familial osteoarthritis, may play a role in pain sensitization after the development of osteoarthritis (PMID:28741447)
• Mutation in COL11A2 gene is associated with Stargardt disease as well as Stickler’s Syndrome . (PMID:30156925)
• rs986522(C) significantly increased the risk of lumbar disc degeneration in Chinese Han females. (PMID:30548218)
• Genetic variant of COL11A2 gene is functionally associated with developmental dysplasia of the hip in Chinese Han population. (PMID:32396528)
• Exon-Trapping Assay Improves Clinical Interpretation of COL11A1 and COL11A2 Intronic Variants in Stickler Syndrome Type 2 and Otospondylomegaepiphyseal Dysplasia. (PMID:33348901)
• Association Between COL5a1, COL11a1, and COL11a2 Gene Variations and Rotator Cuff Tendinopathy in Young Athletes. (PMID:34009784)
• The Association of Variants within Types V and XI Collagen Genes with Knee Joint Laxity Measurements. (PMID:36553626)
• COL11A2 as a candidate gene for vertebral malformations and congenital scoliosis. (PMID:37462524)
• Autosomal recessive otospondylo-mega-epiphyseal dysplasia: comprehensive clinical review of a pediatric cohort. (PMID:37646720)

Cross-species orthologs

3 orthologs

Organism	Symbol	Gene ID
danio_rerio	col11a2	ENSDARG00000012422
mus_musculus	Col11a2	ENSMUSG00000024330
rattus_norvegicus	Col11a2	ENSRNOG00000000463

Paralogs (37): COL9A2 (ENSG00000049089), COL23A1 (ENSG00000050767), COL11A1 (ENSG00000060718), COL17A1 (ENSG00000065618), COL5A3 (ENSG00000080573), COL4A4 (ENSG00000081052), COL16A1 (ENSG00000084636), COL9A3 (ENSG00000092758), COL20A1 (ENSG00000101203), COL1A1 (ENSG00000108821), COL9A1 (ENSG00000112280), COL7A1 (ENSG00000114270), COL21A1 (ENSG00000124749), COL5A1 (ENSG00000130635), COL4A2 (ENSG00000134871), COL2A1 (ENSG00000139219), COL6A1 (ENSG00000142156), COL6A2 (ENSG00000142173), EDA (ENSG00000158813), COL26A1 (ENSG00000160963), COL1A2 (ENSG00000164692), COL3A1 (ENSG00000168542), COL4A3 (ENSG00000169031), COL22A1 (ENSG00000169436), COL24A1 (ENSG00000171502), COL18A1 (ENSG00000182871), EMID1 (ENSG00000186998), COL4A1 (ENSG00000187498), COL4A5 (ENSG00000188153), COL25A1 (ENSG00000188517), COL27A1 (ENSG00000196739), COL13A1 (ENSG00000197467), COL4A6 (ENSG00000197565), COL5A2 (ENSG00000204262), COL15A1 (ENSG00000204291), COLQ (ENSG00000206561), COL28A1 (ENSG00000215018)

Protein

Protein identifiers

Collagen alpha-2(XI) chain — P13942 (reviewed: P13942)

All UniProt accessions (4): P13942, A0A0C4DFS1, H0YIS1, Q4VXY6

UniProt curated annotations — full annotation on UniProt →

Function. May play an important role in fibrillogenesis by controlling lateral growth of collagen II fibrils.

Subunit / interactions. Trimers composed of three different chains: alpha 1(XI), alpha 2(XI), and alpha 3(XI). Alpha 3(XI) is a post-translational modification of alpha 1(II). Alpha 1(V) can also be found instead of alpha 3(XI)=1(II).

Subcellular location. Secreted. Extracellular space. Extracellular matrix.

Post-translational modifications. Prolines at the third position of the tripeptide repeating unit (G-X-Y) are hydroxylated in some or all of the chains. A disulfide-bonded peptide called proline/arginine-rich protein or PARP is released from the N-terminus during extracellular processing and is subsequently retained in the cartilage matrix from which it can be isolated in significant amounts.

Disease relevance. Otospondylomegaepiphyseal dysplasia, autosomal dominant (OSMEDA) [MIM:184840] An autosomal dominant form of otospondylomegaepiphyseal dysplasia, a disorder characterized by sensorineural deafness, enlarged epiphyses, mild platyspondyly, and disproportionate shortness of the limbs. Total body length is normal. Typical facial features are mid-face hypoplasia, short upturned nose and depressed nasal bridge. Most patients have Pierre Robin sequence including an opening in the roof of the mouth (cleft palate) and a small lower jaw (micrognathia). Ocular symptoms are absent. Some patients have early-onset osteoarthritis. The disease is caused by variants affecting the gene represented in this entry. Otospondylomegaepiphyseal dysplasia, autosomal recessive (OSMEDB) [MIM:215150] An autosomal recessive form of otospondylomegaepiphyseal dysplasia, a disorder characterized by sensorineural deafness, enlarged epiphyses, mild platyspondyly, and disproportionate shortness of the limbs. Total body length is normal. Typical facial features are mid-face hypoplasia, short upturned nose and depressed nasal bridge. Most patients have Pierre Robin sequence including an opening in the roof of the mouth (cleft palate) and a small lower jaw (micrognathia). Ocular symptoms are absent. Some patients have early-onset osteoarthritis. The disease is caused by variants affecting the gene represented in this entry. Deafness, autosomal dominant, 13 (DFNA13) [MIM:601868] A form of non-syndromic sensorineural hearing loss. Sensorineural deafness results from damage to the neural receptors of the inner ear, the nerve pathways to the brain, or the area of the brain that receives sound information. The disease is caused by variants affecting the gene represented in this entry. Deafness, autosomal recessive, 53 (DFNB53) [MIM:609706] A form of non-syndromic sensorineural deafness characterized by prelingual, profound, non-progressive hearing loss. Sensorineural deafness results from damage to the neural receptors of the inner ear, the nerve pathways to the brain, or the area of the brain that receives sound information. The disease is caused by variants affecting the gene represented in this entry. Fibrochondrogenesis 2 (FBCG2) [MIM:614524] A severe skeletal dysplasia characterized by a flat midface, short long bones, short ribs with broad metaphyses, and vertebral bodies that show distinctive hypoplastic posterior ends and rounded anterior ends, giving the vertebral bodies a pinched appearance on lateral radiographic views. The chest is small, causing perinatal respiratory problems which usually, but not always, result in lethality. Affected individuals who survive the neonatal period have high myopia, mild to moderate hearing loss, and severe skeletal dysplasia. The disease is caused by variants affecting the gene represented in this entry.

Domain organisation. The C-terminal propeptide, also known as COLFI domain, have crucial roles in tissue growth and repair by controlling both the intracellular assembly of procollagen molecules and the extracellular assembly of collagen fibrils. It binds a calcium ion which is essential for its function.

Similarity. Belongs to the fibrillar collagen family.

Isoforms (9)

UniProt ID	Names	Canonical?
P13942-1	1	yes
P13942-2	2
P13942-3	3
P13942-4	4
P13942-5	5
P13942-6	6
P13942-7	7
P13942-8	8
P13942-9	9

RefSeq proteins (9): NP_001157243, NP_001411037, NP_001411038, NP_001411039, NP_001411040, NP_001411041, NP_542410, NP_542411, NP_542412 (=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR000885	Fib_collagen_C	Domain
IPR001791	Laminin_G	Domain
IPR008160	Collagen	Repeat
IPR013320	ConA-like_dom_sf	Homologous_superfamily
IPR048287	TSPN-like_N	Domain
IPR050149	Collagen_superfamily	Family

Pfam: PF01391, PF01410, PF02210

UniProt features (95 total): compositionally biased region 23, sequence variant 19, sequence conflict 19, domain 10, region of interest 5, binding site 5, disulfide bond 5, splice variant 5, signal peptide 1, chain 1, propeptide 1, glycosylation site 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-P13942-F1	50.18	0.13

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Ligand- & substrate-binding residues (5): 1589; 1591; 1592; 1594; 1597

Disulfide bonds (5): 1571–1603, 1577, 1594, 1612–1733, 1655–1689

Glycosylation sites (1): 1604

Function

Pathways and Gene Ontology

Reactome pathways

7 pathways

ID	Pathway
R-HSA-1442490	Collagen degradation
R-HSA-1650814	Collagen biosynthesis and modifying enzymes
R-HSA-2022090	Assembly of collagen fibrils and other multimeric structures
R-HSA-3000171	Non-integrin membrane-ECM interactions
R-HSA-8874081	MET activates PTK2 signaling
R-HSA-8948216	Collagen chain trimerization
R-HSA-9925563	Developmental Lineage of Pancreatic Ductal Cells

MSigDB gene sets: 417 (showing top): GSE45365_HEALTHY_VS_MCMV_INFECTION_CD8_TCELL_IFNAR_KO_DN, CREL_01, CHIBA_RESPONSE_TO_TSA_UP, GOBP_COLLAGEN_FIBRIL_ORGANIZATION, GOBP_CARTILAGE_DEVELOPMENT, GOBP_SKELETAL_SYSTEM_DEVELOPMENT, GOBP_SENSORY_PERCEPTION_OF_MECHANICAL_STIMULUS, GOCC_COLLAGEN_TRIMER, GRAESSMANN_APOPTOSIS_BY_DOXORUBICIN_UP, GRAESSMANN_RESPONSE_TO_MC_AND_DOXORUBICIN_UP, AP2_Q3, GGGTGGRR_PAX4_03, NKX61_01, NFKB_C, IRF7_01

GO Biological Process (9): skeletal system development (GO:0001501), sensory perception of sound (GO:0007605), collagen fibril organization (GO:0030199), cartilage development (GO:0051216), roof of mouth development (GO:0060021), soft palate development (GO:0060023), tissue homeostasis (GO:0001894), chondrocyte differentiation (GO:0002062), skeletal system morphogenesis (GO:0048705)

GO Molecular Function (5): extracellular matrix structural constituent conferring tensile strength (GO:0030020), protein-macromolecule adaptor activity (GO:0030674), metal ion binding (GO:0046872), extracellular matrix structural constituent (GO:0005201), protein binding (GO:0005515)

GO Cellular Component (7): extracellular region (GO:0005576), collagen type II trimer (GO:0005585), collagen type XI trimer (GO:0005592), endoplasmic reticulum lumen (GO:0005788), extracellular matrix (GO:0031012), collagen trimer (GO:0005581), ribosome (GO:0005840)

Reactome top-level categories

Rollup of top-6 pathways:

Category	Pathways
Collagen formation	2
Degradation of the extracellular matrix	1
Extracellular matrix organization	1
MET promotes cell motility	1
Collagen biosynthesis and modifying enzymes	1
Developmental Cell Lineages of the Exocrine Pancreas	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
skeletal system development	2
anatomical structure development	2
fibrillar collagen trimer	2
system development	1
sensory perception of mechanical stimulus	1
extracellular matrix organization	1
animal organ development	1
connective tissue development	1
secondary palate development	1
multicellular organismal-level homeostasis	1
anatomical structure homeostasis	1
cell differentiation	1
cartilage development	1
animal organ morphogenesis	1
extracellular matrix structural constituent	1
protein binding	1
molecular adaptor activity	1
cation binding	1
structural molecule activity	1
extracellular matrix	1
binding	1
cellular anatomical structure	1
endoplasmic reticulum	1
intracellular organelle lumen	1
external encapsulating structure	1
protein-containing complex	1
intracellular membraneless organelle	1

Protein interactions and networks

STRING

1562 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
COL11A2	LHFPL5	Q8TAF8	856
COL11A2	COL2A1	P02458	840
COL11A2	RXRB	P28702	804
COL11A2	HSD17B8	Q92506	798
COL11A2	KIFC1	Q9BW19	795
COL11A2	RGL2	O15211	786
COL11A2	RPS18	P25232	786
COL11A2	SLC39A7	Q92504	780
COL11A2	PFDN6	O15212	702
COL11A2	HAPLN1	P10915	680
COL11A2	RING1	Q06587	660
COL11A2	PCOLCE	Q15113	636
COL11A2	COL5A1	P20908	622
COL11A2	MIA	Q16674	608
COL11A2	LHFPL3	Q86UP9	605

IntAct

9 interactions, top by confidence:

A	B	Type	Score
COL11A2	DDR2	psi-mi:“MI:0407”(direct interaction)	0.560
DDR2	COL11A2	psi-mi:“MI:0407”(direct interaction)	0.560
COL11A2	RPL9	psi-mi:“MI:0915”(physical association)	0.400
COL11A2	ANXA7	psi-mi:“MI:0915”(physical association)	0.370
COL11A2	PIN1	psi-mi:“MI:0915”(physical association)	0.370
TK1	COL11A2	psi-mi:“MI:0915”(physical association)	0.370
WDR20	POLR1C	psi-mi:“MI:0914”(association)	0.350
LTK	AIP	psi-mi:“MI:2364”(proximity)	0.270

BioGRID (12): RPL9 (Proximity Label-MS), COL11A2 (Affinity Capture-RNA), COL11A2 (PCA), COL11A2 (Proximity Label-MS), COL11A2 (Cross-Linking-MS (XL-MS)), COL11A2 (Affinity Capture-MS), COL11A2 (Affinity Capture-MS), COL11A2 (Co-fractionation), COL11A2 (Affinity Capture-MS), COL11A2 (Two-hybrid), COL11A2 (Two-hybrid), COL11A2 (Two-hybrid)

ESM2 similar proteins: A0A060WQA3, A0MSJ1, A5PN28, A6NHN0, A8WGB1, A8WR59, B2RNN3, B7Z0K8, C7DZK3, O35167, O35348, O76368, O88207, P0C862, P12107, P13942, P20908, P20909, P23805, P25067, P25318, P25940, P42916, P83371, P98085, Q03637, Q07092, Q07563, Q0II24, Q0VF58, Q17RW2, Q30D77, Q32S24, Q3MI99, Q4ZJM7, Q4ZJN1, Q60467, Q61245, Q64739, Q6UXH8

Diamond homologs: A0MSJ1, C7DZK3, O42350, O88207, P02452, P02457, P02458, P02459, P02460, P02461, P02466, P05997, P08121, P12105, P12107, P13941, P13942, P20908, P20909, Q17RW2, Q30D77, Q32S24, Q3U962, Q5QNQ9, Q60467, Q61245, Q64739, Q6P4Z2, Q80ZF0, Q8IZC6, Q91717, Q9JI03, Q9YIB4, B8V7R6, O46392, O93484, P02453, P02454, P02465, P02467

SIGNOR signaling

1 interactions.

A	Effect	B	Mechanism
SOX9	“up-regulates quantity by expression”	COL11A2	“transcriptional regulation”

Disease & clinical

Clinical variants and AI predictions

ClinVar

3179 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	109
Likely pathogenic	70
Uncertain significance	1012
Likely benign	1464
Benign	126

Top pathogenic / likely-pathogenic (30)

Variant ID	HGVS	Classification
1252015	NM_080680.3(COL11A2):c.1871dup (p.Gly625fs)	Pathogenic
1322103	NM_080680.3(COL11A2):c.328C>T (p.Arg110Ter)	Pathogenic
1322104	NM_080680.3(COL11A2):c.2540del (p.Gly847fs)	Pathogenic
1351259	NM_080680.3(COL11A2):c.4265dup (p.Gly1423_Glu1424insTer)	Pathogenic
1357508	NM_080680.3(COL11A2):c.3545del (p.Pro1182fs)	Pathogenic
1371095	NM_080680.3(COL11A2):c.272G>A (p.Arg91Gln)	Pathogenic
1379760	NM_080680.3(COL11A2):c.1957del (p.Thr653fs)	Pathogenic
1402330	NM_080680.3(COL11A2):c.3496G>T (p.Glu1166Ter)	Pathogenic
1451542	NM_080680.3(COL11A2):c.3032del (p.Pro1011fs)	Pathogenic
1452394	NM_080680.3(COL11A2):c.4519C>T (p.Gln1507Ter)	Pathogenic
1459216	NM_080680.3(COL11A2):c.1636C>T (p.Arg546Ter)	Pathogenic
160366	NM_080680.3(COL11A2):c.109G>T (p.Ala37Ser)	Pathogenic
1701500	NM_080680.3(COL11A2):c.4123-1G>T	Pathogenic
1708726	NM_080680.3(COL11A2):c.3133G>T (p.Gly1045Ter)	Pathogenic
17120	NM_080680.3(COL11A2):c.4392+1G>A	Pathogenic
17122	NM_080680.3(COL11A2):c.2822_2848del (p.Glu941_Pro950delinsAla)	Pathogenic
17123	NM_080680.3(COL11A2):c.4322G>A (p.Gly1441Glu)	Pathogenic
17125	NM_080680.3(COL11A2):c.2423G>A (p.Gly808Glu)	Pathogenic
17126	NM_080680.3(COL11A2):c.2492C>A (p.Ser831Ter)	Pathogenic
17128	NM_080680.3(COL11A2):c.3991C>T (p.Arg1331Ter)	Pathogenic
17130	NM_080680.3(COL11A2):c.3962del	Pathogenic
1804120	NM_080680.3(COL11A2):c.2086del (p.Glu696fs)	Pathogenic
1951094	NM_080680.3(COL11A2):c.874C>T (p.Gln292Ter)	Pathogenic
1975014	NM_080680.3(COL11A2):c.1672C>T (p.Arg558Ter)	Pathogenic
2022159	NM_080680.3(COL11A2):c.2658del (p.Pro888fs)	Pathogenic
2022530	NM_080680.3(COL11A2):c.1962del (p.Thr656fs)	Pathogenic
2098356	NM_080680.3(COL11A2):c.3833dup (p.Gly1279fs)	Pathogenic
2117536	NM_080680.3(COL11A2):c.1586del (p.Gly529fs)	Pathogenic
2118997	NM_080680.3(COL11A2):c.1076_1077del (p.Glu359fs)	Pathogenic
2130254	NM_080680.3(COL11A2):c.966del (p.Thr323fs)	Pathogenic

SpliceAI

6632 predictions. Top by Δscore:

Variant	Effect	Δscore
6:33163815:GTGT:G	acceptor_gain	1.0000
6:33163817:GT:G	acceptor_gain	1.0000
6:33163819:C:CA	acceptor_loss	1.0000
6:33163819:C:CC	acceptor_gain	1.0000
6:33163822:C:CT	acceptor_gain	1.0000
6:33163823:A:T	acceptor_gain	1.0000
6:33164255:T:TA	donor_gain	1.0000
6:33164261:TCCCA:T	donor_loss	1.0000
6:33164262:CCCAC:C	donor_loss	1.0000
6:33164263:CCACC:C	donor_loss	1.0000
6:33164264:CACCT:C	donor_loss	1.0000
6:33164265:A:T	donor_loss	1.0000
6:33164266:CCTG:C	donor_loss	1.0000
6:33164317:G:C	donor_gain	1.0000
6:33164321:AT:A	donor_gain	1.0000
6:33164322:T:TA	donor_gain	1.0000
6:33164388:T:TA	donor_gain	1.0000
6:33164469:GAGAA:G	acceptor_gain	1.0000
6:33164470:AGAA:A	acceptor_gain	1.0000
6:33164471:GAA:G	acceptor_gain	1.0000
6:33164472:AA:A	acceptor_gain	1.0000
6:33164472:AAC:A	acceptor_loss	1.0000
6:33164473:AC:A	acceptor_loss	1.0000
6:33164474:C:CC	acceptor_gain	1.0000
6:33164474:C:T	acceptor_loss	1.0000
6:33164475:T:C	acceptor_loss	1.0000
6:33164847:CTCAC:C	donor_loss	1.0000
6:33164850:A:AC	donor_gain	1.0000
6:33164851:C:CC	donor_gain	1.0000
6:33164851:CCTG:C	donor_gain	1.0000

AlphaMissense

10817 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
6:33164906:G:C	C1603W	1.000
6:33164907:C:G	C1603S	1.000
6:33164907:C:T	C1603Y	1.000
6:33164908:A:G	C1603R	1.000
6:33164908:A:T	C1603S	1.000
6:33165578:A:G	L1574P	1.000
6:33165586:G:C	C1571W	1.000
6:33165587:C:T	C1571Y	1.000
6:33163688:A:C	F1734C	0.999
6:33163688:A:G	F1734S	0.999
6:33164405:G:C	S1644R	0.999
6:33164405:G:T	S1644R	0.999
6:33164407:T:G	S1644R	0.999
6:33164412:A:G	L1642P	0.999
6:33164420:G:C	F1639L	0.999
6:33164420:G:T	F1639L	0.999
6:33164421:A:C	F1639C	0.999
6:33164422:A:G	F1639L	0.999
6:33164907:C:A	C1603F	0.999
6:33164942:G:C	N1591K	0.999
6:33164942:G:T	N1591K	0.999
6:33164946:G:T	P1590H	0.999
6:33164949:T:C	D1589G	0.999
6:33164959:A:C	Y1586D	0.999
6:33165587:C:A	C1571F	0.999
6:33165587:C:G	C1571S	0.999
6:33165588:A:G	C1571R	0.999
6:33165588:A:T	C1571S	0.999
6:33166799:C:T	G1420E	0.999
6:33166808:C:T	G1417E	0.999

dbSNP variants (sampled 300 via entrez): RS1000091006 (6:33181588 C>T), RS1000116715 (6:33188793 A>C), RS1000174480 (6:33162309 A>G), RS1000260021 (6:33175499 C>T), RS1000355634 (6:33168444 A>C), RS1000411560 (6:33175880 G>A), RS1000420177 (6:33181953 G>A), RS1000491541 (6:33194538 G>C,T), RS1000612226 (6:33194223 A>G), RS1000892992 (6:33176659 C>T), RS1001105186 (6:33187567 A>G), RS1001125057 (6:33190663 G>A), RS1001222814 (6:33188872 G>A), RS1001257347 (6:33181334 C>A,T), RS1001309151 (6:33187917 G>A)

Disease associations

OMIM: gene MIM:120290 | disease phenotypes: MIM:215150, MIM:601868, MIM:184840, MIM:277610, MIM:609706, MIM:614524, MIM:241500, MIM:245600, MIM:128600, MIM:257350, MIM:257850, MIM:614211, MIM:190685

GenCC curated gene-disease

Disease	Classification	Inheritance
otospondylomegaepiphyseal dysplasia, autosomal dominant	Definitive	Autosomal dominant
otospondylomegaepiphyseal dysplasia, autosomal recessive	Definitive	Autosomal recessive
autosomal dominant nonsyndromic hearing loss 13	Definitive	Autosomal dominant
autosomal recessive nonsyndromic hearing loss 53	Definitive	Autosomal recessive
otospondylomegaepiphyseal dysplasia	Definitive	Autosomal dominant
fibrochondrogenesis	Supportive	Autosomal dominant
autosomal dominant nonsyndromic hearing loss	Supportive	Autosomal dominant
hearing loss, autosomal recessive	Supportive	Autosomal recessive

ClinGen Gene-Disease Validity (4)

Expert-panel classifications — Definitive > Strong > Moderate > Limited > Disputed > Refuted.

Disease	Classification	Inheritance
nonsyndromic genetic hearing loss	Definitive	AD
otospondylomegaepiphyseal dysplasia	Definitive	AD
otospondylomegaepiphyseal dysplasia	Definitive	AR
nonsyndromic genetic hearing loss	Moderate	AR

Mondo (23): otospondylomegaepiphyseal dysplasia, autosomal recessive (MONDO:0044206), autosomal dominant nonsyndromic hearing loss 13 (MONDO:0011159), hearing loss disorder (MONDO:0005365), otospondylomegaepiphyseal dysplasia, autosomal dominant (MONDO:0008490), autosomal recessive nonsyndromic hearing loss 53 (MONDO:0012333), fibrochondrogenesis 2 (MONDO:0013795), infantile hypophosphatasia (MONDO:1010169), connective tissue disorder (MONDO:0003900), Larsen-like syndrome, B3GAT3 type (MONDO:0009511), nonsyndromic genetic hearing loss (MONDO:0019497), conductive hearing loss disorder (MONDO:0020679), sensorineural hearing loss disorder (MONDO:0020678), ear malformation (MONDO:0007500), cystic hygroma (MONDO:0009761), oculodentodigital dysplasia, autosomal recessive (MONDO:0009768)

Orphanet (16): Autosomal recessive otospondylomegaepiphyseal dysplasia (Orphanet:1427), Rare autosomal dominant non-syndromic sensorineural deafness type DFNA (Orphanet:90635), Autosomal dominant otospondylomegaepiphyseal dysplasia (Orphanet:166100), Fibrochondrogenesis (Orphanet:2021), Weissenbacher-Zweymuller syndrome (Orphanet:3450), Rare autosomal recessive non-syndromic sensorineural deafness type DFNB (Orphanet:90636), Infantile hypophosphatasia (Orphanet:247651), Hypophosphatasia (Orphanet:436), Rare genetic deafness (Orphanet:96210), Larsen-like syndrome, B3GAT3 type (Orphanet:284139), Rare non-syndromic genetic deafness (Orphanet:87884), Oculodentodigital dysplasia (Orphanet:2710), OBSOLETE: Inherited retinal disorder (Orphanet:71862), Down syndrome (Orphanet:870), Cystic hygroma (Orphanet:79486)

HPO phenotypes

103 total (30 of 103 shown, HPO-id order):

HPO	Term
HP:0000006	Autosomal dominant inheritance
HP:0000007	Autosomal recessive inheritance
HP:0000160	Narrow mouth
HP:0000162	Glossoptosis
HP:0000175	Cleft palate
HP:0000193	Bifid uvula
HP:0000201	Pierre-Robin sequence
HP:0000260	Wide anterior fontanel
HP:0000272	Malar flattening
HP:0000311	Round face
HP:0000316	Hypertelorism
HP:0000336	Prominent supraorbital ridges
HP:0000343	Long philtrum
HP:0000347	Micrognathia
HP:0000358	Posteriorly rotated ears
HP:0000364	Hearing abnormality
HP:0000369	Low-set ears
HP:0000407	Sensorineural hearing impairment
HP:0000410	Mixed hearing impairment
HP:0000414	Bulbous nose
HP:0000463	Anteverted nares
HP:0000470	Short neck
HP:0000478	Abnormality of the eye
HP:0000486	Strabismus
HP:0000494	Downslanted palpebral fissures
HP:0000518	Cataract
HP:0000520	Proptosis
HP:0000540	Hypermetropia
HP:0000541	Retinal detachment
HP:0000767	Pectus excavatum

GWAS associations

13 associations (top):

Study	Trait	p-value
GCST001613_18	Antineutrophil cytoplasmic antibody-associated vasculitis	1.000000e-71
GCST002160_5	Wegener’s granulomatosis	2.000000e-50
GCST002217_5	Sjögren’s syndrome	9.000000e-25
GCST004748_119	Lung cancer	1.000000e-06
GCST005790_68	Rosacea symptom severity	2.000000e-07
GCST007797_34	Asthma onset (childhood vs adult)	4.000000e-06
GCST007798_48	Asthma	4.000000e-14
GCST007800_17	Asthma (childhood onset)	3.000000e-17
GCST008053_72	Height	3.000000e-13
GCST008365_16	Thyrotoxic hypokalemic periodic paralysis and Graves disease	2.000000e-18
GCST90020028_532	Hip circumference adjusted for BMI	8.000000e-09
GCST90020028_533	Hip circumference adjusted for BMI	5.000000e-10
GCST90020028_534	Hip circumference adjusted for BMI	2.000000e-10

EFO canonical traits (3, from GWAS)

EFO ID	Trait name
EFO:0009180	rosacea severity measurement
EFO:0004847	age at onset
EFO:0008039	BMI-adjusted hip circumference

MeSH disease descriptors (15)

Descriptor	Name	Tree numbers
D003240	Connective Tissue Diseases	C17.300
D004314	Down Syndrome	C10.597.606.360.220; C16.131.077.327; C16.131.260.260; C16.320.180.260
D034381	Hearing Loss	C09.218.458.341; C10.597.751.418.341; C23.888.592.763.393.341
D008607	Intellectual Disability	C10.597.606.360; C23.888.592.604.646; F01.700.687; F03.625.539
D018191	Lymphangioma, Cystic	C04.557.375.450.450
D058499	Retinal Dystrophies	C11.768.585.658
C566612	Deafness, Autosomal Dominant 13 (supp.)
C564609	Deafness, Autosomal Recessive (supp.)
C566453	Deafness, Autosomal Recessive 53 (supp.)
C562524	Fibrochondrogenesis (supp.)
C537874	Larsen syndrome, recessive type (supp.)
C580334	Nonsyndromic Deafness (supp.)
C567605	Oculodentodigital Dysplasia, Autosomal Recessive (supp.)
C535776	Pierre Robin syndrome with fetal chondrodysplasia (supp.)
C537494	Stickler syndrome, type 3 (supp.)

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (1): CHEMBL2364188 (PROTEIN COMPLEX GROUP)

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

33 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Valproic Acid	affects cotreatment, increases expression	4
trichostatin A	affects cotreatment, increases expression	3
Cisplatin	affects cotreatment, affects expression, affects response to substance	2
aristolochic acid I	increases expression	1
bisphenol F	affects cotreatment, decreases methylation	1
triphenyl phosphate	affects expression	1
bisphenol A	decreases methylation	1
sodium arsenite	increases expression	1
benzo(e)pyrene	increases methylation	1
tamibarotene	affects expression	1
CGP 52608	affects binding, increases reaction	1
entinostat	increases expression	1
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	increases expression, affects cotreatment	1
abrine	increases expression	1
dorsomorphin	affects cotreatment, increases expression	1
bisphenol S	affects cotreatment, increases methylation	1
theaflavin-3,3’-digallate	affects expression	1
Fulvestrant	affects cotreatment, decreases methylation, increases methylation	1
Vorinostat	affects cotreatment, increases expression	1
Glyphosate	increases expression	1
Arsenic	affects methylation	1
Benzo(a)pyrene	affects methylation, increases methylation	1
Doxorubicin	decreases expression	1
Methapyrilene	increases methylation	1
Tamoxifen	increases expression	1
Tretinoin	decreases expression	1
Triclosan	decreases expression	1
2,4-Dichlorophenoxyacetic Acid	increases expression	1
Aflatoxin B1	increases methylation	1
Paclitaxel	affects expression, affects cotreatment	1

Clinical trials (associated diseases)

300 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT00205881	PHASE4	COMPLETED	Bilateral Benefit in Adult Users of the HiRes 90K Bionic Ear System
NCT00331539	PHASE4	UNKNOWN	Relationship Between Auto NRT and Behavioural T & C Levels With the Nucleus Freedom Cochlear Implant
NCT00424307	PHASE4	UNKNOWN	Bilateral Cochlear Implant Benefit in Young Children
NCT00765635	PHASE4	COMPLETED	Chlorobutanol, Potassium Carbonate, and Irrigation in Cerumen Removal
NCT03321006	PHASE4	COMPLETED	Treating Hearing Loss to Improve Mood and Cognition in Older Adults
NCT01499901	PHASE3	WITHDRAWN	Comparison of the Bilateral Sequential and Simultaneous Cochlear Implantation in the Deaf Children
NCT02561091	PHASE3	COMPLETED	AM-111 in the Treatment of Acute Inner Ear Hearing Loss
NCT03331627	PHASE3	COMPLETED	Safety and Efficacy of STR001-IT and STR001-ER in Patients With SSHL
NCT05532657	PHASE3	ACTIVE_NOT_RECRUITING	ACHIEVE Brain Health Follow-Up Study
NCT00013455	PHASE2	COMPLETED	Quantifying Auditory Perceptual Learning Following Hearing Aid Fitting
NCT00323427	PHASE2	COMPLETED	Clinical Trial of the Living Well With Hearing Loss Workshop
NCT00552786	PHASE2	COMPLETED	Antioxidation Medication for Noise-induced Hearing Loss
NCT00802425	PHASE2	COMPLETED	Efficacy of AM-111 in Patients With Acute Sensorineural Hearing Loss
NCT01139281	PHASE2	COMPLETED	The Protective Effect of Ginkgo Biloba Extract on Cisplatin-induced Ototoxicity in Humans
NCT01451853	PHASE2	UNKNOWN	SPI-1005 for Prevention and Treatment of Chemotherapy Induced Hearing Loss
NCT01588925	PHASE2	COMPLETED	Hearing Preservation Using Dexamethasone and Hyaluronic Acid for Cochlear Implantation
NCT01773278	PHASE2	RECRUITING	Cholesterol and Antioxidant Treatment in Patients With Smith-Lemli-Opitz Syndrome (SLOS)
NCT02832128	PHASE2	COMPLETED	Evaluating Possible Improvement in Speech and Hearing Tests After 28 Days of Dosing of the Study Drug AUT00063 Compared to Placebo (QuicKfire)
NCT04915183	PHASE2	RECRUITING	Atorvastatin to Reduce Cisplatin-Induced Hearing Loss Among Individuals With Head and Neck Cancer
NCT05258773	PHASE2	COMPLETED	Evaluation of the Presence of SENS-401 in the Perilymph
NCT06340633	PHASE2	RECRUITING	SPI-1005 in Adults Receiving Cochlear Implant
NCT00582946	PHASE1	COMPLETED	Wide-Bandwidth Open Canal Hearing Aid For Better Multitalker Speech Understanding
NCT00584155	PHASE1	WITHDRAWN	Protection From Cisplatin Ototoxicity by Lactated Ringers
NCT01206829	PHASE1	UNKNOWN	Hearing Impairment, Cognitive Therapy and Coping
NCT01256229	PHASE1	COMPLETED	Outcomes In Children With Developmental Delay And Deafness
NCT01343394	PHASE1	WITHDRAWN	Safety of Autologous Human Umbilical Cord Blood Mononuclear Fraction to Treat Acquired Hearing Loss in Children
NCT01452607	PHASE1	COMPLETED	Study to Evaluate the Safety and Pharmacokinetics of SPI-1005
NCT02259595	PHASE1	COMPLETED	Study to Determine the Safety, Tolerability, and Pharmacokinetic Profile of HPN-07 and HPN-07 Plus NAC
NCT04041440	PHASE1	COMPLETED	Speech Recognition Training in Children With Hearing Loss
NCT07218913	PHASE1	RECRUITING	Testing the Addition of Pedmark to Cisplatin Chemotherapy for Reducing Drug-Induced Ear Damage in Men With Stage II-III Metastatic Testicular Germ Cell Tumors
NCT00486577	PHASE2/PHASE3	COMPLETED	Chronic Electrical Stimulation of the Auditory Cortex for Intractable Tinnitus
NCT00789061	PHASE2/PHASE3	UNKNOWN	Applying Proton Pump Inhibitor to Prevent and Treat Acute Fluctuating Hearing Loss in Patients With SLC26A4 Mutation
NCT01423409	PHASE2/PHASE3	COMPLETED	Multicenter Trial Assessing an Innovative VAS of Pain Among Deaf People
NCT05786378	PHASE2/PHASE3	UNKNOWN	Assessment of The Efficacy of Intratympanic Platelet Rich Plasma for Treatment of Sensorineural Hearing Loss.
NCT01108601	PHASE1/PHASE2	UNKNOWN	Transtympanic Ringer’s Lactate for the Prevention of Cisplatin Ototoxicity
NCT01621256	PHASE1/PHASE2	COMPLETED	Efficacy, Safety, and Tolerability of Ancrod in Patients With Sudden Hearing Loss
NCT06370351	PHASE1/PHASE2	RECRUITING	A Phase I/II Clinical Trial with SENS-501 in Children Suffering from Severe to Profound Hearing Loss Due to Otoferlin (OTOF) Mutations
NCT06545175	PHASE1/PHASE2	RECRUITING	Intracochlear Application of VSF1.01 for the Reduction of Cochlear Implant Surgery Related Trauma
NCT07304024	PHASE1/PHASE2	RECRUITING	A Treatment for a Form of Age-Related Central Auditory Processing Disorder Consisting of Clemastine Fumarate Plus Engineered Sound
NCT01109576	EARLY_PHASE1	COMPLETED	Workshops for Veterans With Vision and Hearing Loss